Meeting
2020 ASCO Virtual Scientific Program
Circulating tumor DNA (ctDNA) analysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.
Authors
Si-Yu Wang
Sun Yat-sen University Cancer Center, Guangzhou, China
Si-Yu Wang , Ning Li , Wei Ou , Chao Cheng , Peng-Peng Kuang , Hui-Qi Wu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Biologic Correlates
Clinical Trial Registration Number
NCT03465241 and NCT03172156
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9023)
DOI
10.1200/JCO.2020.38.15_suppl.9023
Abstract #
9023
Poster Bd #
216
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Dynamic monitoring circulating tumor DNA in plasma samples by PEAC technology for patients with early-stage non–small cell lung cancer after surgery.
First Author: Ning Li
Poster
2022 ASCO Annual Meeting
Postoperative ctDNA in indicating the recurrence risk and monitoring the effect of adjuvant therapy in surgical non–small cell lung cancers.
First Author: Xiaoru Tian
Poster
2020 ASCO Virtual Scientific Program
Circulating tumor DNA as a promising biomarker of relapse risk for stage II-III colorectal cancer.
First Author: Gong Chen
Poster
2019 ASCO Annual Meeting
A plasma-only integrated genomic and epigenomic circulating tumor DNA (ctDNA) assay to inform recurrence risk in colorectal cancer (CRC).
First Author: Aparna Raj Parikh